Jeryl Lynn
Jeryl Lynn are strains of mumps virus used in the Mumpsvax mumps vaccine made by Merck. The strains are named after Jeryl Lynn Hilleman. In 1963 Ms. Hilleman's father Dr. Maurice Hilleman, was leading efforts to produce a mumps vaccine for Merck. He cultured the Mumps virus from her throat, and in 1967 a vaccine was produced from this which is now widely used.[1]
Mumpsvax
The Jeryl Lynn strains used in the manufacture of Mumpsvax later turned out to contain two distinguishable viral substrains, JL1 and JL2.[2] Further research showed that the JL1 strain was preferentially selected by propagation in Vero and CEF cell cultures. The JL2 strain was preferentially selected by passage in embryonated chicken eggs.[3]
In the U.S.A. the Jeryl Lynn strain-based vaccines supplanted the previous, killed virus, vaccine in 1978.[1]
Vaccine controversy
Dr. Hilleman created nine of the 14 vaccines currently included in mandatory vaccination schedules to control childhood diseases. Hilleman's ambition is to eliminate all childhood infections. In order to maximize the chances that more children would receive the vaccines he developed, he worked to find ways to combine multiple vaccines into a single shot. In 1971, he succeeded in getting his MMR vaccine developed, but when it was finally introduced into the UK in 1988, it was quickly removed from the market due to side effects. The Jeryl Lynn mumps vaccine strain is one component of the controversial MMR vaccine, at the heart of the acrimonious debate in the United Kingdom and elsewhere, over whether the National Health Service should make single jab vaccinations more readily available. A later version ran into controversy, when UK pediatric gastroenterologist Andrew Wakefield first recommended separation of the vaccinations into single jabs. At the same time, Wakefield also reported signs of a possible link between a possible new syndrome involving bowel disorders and autism (later to be described as autistic enterocolitis).
Footnotes
- ^ a b World Health Organization (1998). "The Mumps Vaccine". Immunization, Vaccines and Biologicals. Retrieved 2006-05-24.
{{cite web}}: Unknown parameter|month=ignored (help) - ^ Amexis G, Oeth P, Abel K, Ivshina A, Pelloquin F, Cantor C, Braun A, Chumakov K, Brau A (2001). "Quantitative mutant analysis of viral quasispecies by chip-based matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry". Proc Natl Acad Sci U S A. 98 (21): 12097–102. PMID 11593021.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Amexis G, Rubin S, Chizhikov V, Pelloquin F, Carbone K, Chumakov K (2002). "Sequence diversity of Jeryl Lynn strain of mumps virus: quantitative mutant analysis for vaccine quality control". Virology. 300 (2): 171–9. PMID 12350348.
{{cite journal}}: CS1 maint: multiple names: authors list (link)- Complete genome of JL1 - Amexis,G., Rubin,S., Chizhikov,V., Pelloquin,F., Carbone,K., Chumakov,K. (2002). "Mumps virus (STRAIN JERYL-LYNN) live vaccine major component, complete genome". Virology.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Complete genome of JL2 - Amexis,G., Rubin,S., Chizhikov,V., Pelloquin,F., Carbone,K., Chumakov,K. (2002). "Mumps virus (STRAIN JERYL-LYNN) live vaccine minor component JL2, complete genome". Virology.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
- Complete genome of JL1 - Amexis,G., Rubin,S., Chizhikov,V., Pelloquin,F., Carbone,K., Chumakov,K. (2002). "Mumps virus (STRAIN JERYL-LYNN) live vaccine major component, complete genome". Virology.